- Home
- WETH vs BIAF Comparison
WETH vs BIAF Comparison
Compare WETH & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WETH
- BIAF
- Stock Information
- Founded
- WETH 1992
- BIAF 2014
- Country
- WETH China
- BIAF United States
- Employees
- WETH N/A
- BIAF N/A
- Industry
- WETH
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- WETH
- BIAF Health Care
- Exchange
- WETH Nasdaq
- BIAF Nasdaq
- Market Cap
- WETH 10.9M
- BIAF 13.0M
- IPO Year
- WETH N/A
- BIAF 2022
- Fundamental
- Price
- WETH $2.18
- BIAF $2.66
- Analyst Decision
- WETH
- BIAF Hold
- Analyst Count
- WETH 0
- BIAF 1
- Target Price
- WETH N/A
- BIAF N/A
- AVG Volume (30 Days)
- WETH 320.3K
- BIAF 3.5M
- Earning Date
- WETH 10-09-2025
- BIAF 11-13-2025
- Dividend Yield
- WETH N/A
- BIAF N/A
- EPS Growth
- WETH 63.71
- BIAF N/A
- EPS
- WETH 0.63
- BIAF N/A
- Revenue
- WETH $42,877,572.00
- BIAF $7,681,059.00
- Revenue This Year
- WETH N/A
- BIAF N/A
- Revenue Next Year
- WETH N/A
- BIAF $20.04
- P/E Ratio
- WETH $3.47
- BIAF N/A
- Revenue Growth
- WETH 5.58
- BIAF 4.99
- 52 Week Low
- WETH $0.76
- BIAF $2.34
- 52 Week High
- WETH $2.41
- BIAF $46.53
- Technical
- Relative Strength Index (RSI)
- WETH 76.22
- BIAF 48.14
- Support Level
- WETH $1.65
- BIAF $2.43
- Resistance Level
- WETH $1.89
- BIAF $3.50
- Average True Range (ATR)
- WETH 0.24
- BIAF 0.33
- MACD
- WETH 0.05
- BIAF -0.10
- Stochastic Oscillator
- WETH 81.20
- BIAF 20.04
About WETH Wetouch Technology Inc.
Wetouch Technology Inc is a touch panel supplier focused on R & D, production and sales of touch screen products. It offers touchscreens for a variety of applications, including GPS/car entertainment panels for automotive industry, industrial human-machine interface, financial and banking terminals, point of sale, lottery and gaming machines, smart home, robots and charging stations. The company sells touchscreen products both domestically in China and internationally, covering the majority of areas in China, Taiwan, South Korea, and Germany.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.